RU99113041A - HEMOGENEOUS PREFERENCES CONTAINING HIGH CONCENTRATION OF STEROIDS FOR THE PRODUCTION OF LOW-DOSED SOLID AND SEMI-HARD PHARMACEUTICAL PRODUCTS - Google Patents

HEMOGENEOUS PREFERENCES CONTAINING HIGH CONCENTRATION OF STEROIDS FOR THE PRODUCTION OF LOW-DOSED SOLID AND SEMI-HARD PHARMACEUTICAL PRODUCTS

Info

Publication number
RU99113041A
RU99113041A RU99113041/14A RU99113041A RU99113041A RU 99113041 A RU99113041 A RU 99113041A RU 99113041/14 A RU99113041/14 A RU 99113041/14A RU 99113041 A RU99113041 A RU 99113041A RU 99113041 A RU99113041 A RU 99113041A
Authority
RU
Russia
Prior art keywords
steroids
high concentration
excipient
semi
low
Prior art date
Application number
RU99113041/14A
Other languages
Russian (ru)
Other versions
RU2178694C2 (en
Inventor
Граве Детлеф
Хезель Петер
Мелльманн Петер
Тимпе Карстен
Диттген Михаель
Маттей Клаус
Original Assignee
Йенафарм Гмбх Энд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19652196A external-priority patent/DE19652196A1/en
Application filed by Йенафарм Гмбх Энд Ко. Кг filed Critical Йенафарм Гмбх Энд Ко. Кг
Publication of RU99113041A publication Critical patent/RU99113041A/en
Application granted granted Critical
Publication of RU2178694C2 publication Critical patent/RU2178694C2/en

Links

Claims (6)

1. Гомогенные преформции, содержащие стероиды в высокой концентрации, для изготовления низкодозированных твердых и полутвердых фармацевтических препаратов с концентрированным содержанием 0,001 - 1% стероидного веса, получаемые посредством испарения диспергатора, содержащего стероидальное активное вещество, из суспензии с диспергированным, фармацевтически обычным вспомогательным веществом, причем с помощью распыления производится туман, средний диаметр капель которого больше чем средний диаметр частиц вспомогательного вещества, а максимальная зернистость высушенных частиц стероидосодержащих преформции увеличивается менее чем на 30% по сравнению с зернистостью вспомогательного вещества.1. Homogeneous preforms containing steroids in high concentration for the manufacture of low-dose solid and semi-solid pharmaceutical preparations with a concentrated content of 0.001 to 1% steroid weight, obtained by vaporizing a dispersant containing a steroidal active substance from a suspension with a dispersed pharmaceutically ordinary excipient, moreover spraying produces fog, the average droplet diameter of which is greater than the average particle diameter of the excipient, and the poppy imalnaya graininess steroidosoderzhaschih preformtsii dried particles is increased by at least 30% compared with the grain size of the excipient. 2. Гомогенные преформции, содержащие стероиды высокой концентрации, для изготовления низкодозированных твердых и полутвердых фармацевтических препаратов в соответствии с претензией 1, отличаются тем, что концентрация стероидального активного вещества составляет 0,001 - 50% веса. 2. Homogeneous preforms containing high concentration steroids for the manufacture of low-dose solid and semi-solid pharmaceutical preparations in accordance with claim 1, characterized in that the concentration of the steroidal active substance is 0.001 to 50% by weight. 3. Гомогенные преформции, содержащие стероиды высокой концентрации, в соответствии с претензиями 1 и 2, отличаются тем, что обычное фармацевтическое вспомогательное вещество находится в микронизированной форме. 3. Homogeneous preforms containing high concentration steroids, in accordance with claims 1 and 2, are characterized in that the usual pharmaceutical excipient is in micronized form. 4. Гомогенные преформции, содержащие стероиды высокой концентрации, в соответствии с претензиями от 1 до 3, отличаются тем, что стероидальное активное вещество представляет собой по крайней мере одну составную часть из группы сексуальных гормонов. 4. Homogeneous preformations containing high concentration steroids, in accordance with claims 1 to 3, are characterized in that the steroidal active substance is at least one constituent of the group of sex hormones. 5. Технология для изготовления гомогенных преформции, содержащих стероиды в высокой концентрации, для низкодозированных твердых и полутвердых фармацевтических препаратов с концентрированным содержанием 0,001 - 1% стероидного веса, отличается тем, что из суспензии с диспергированным, обычным фармацевтическим вспомогательным веществом выпаривается диспергатор, содержащий стероидальное активное вещество, причем производится с помощью распыления туман, средний диаметр капель которого больше чем средний диаметр частиц вспомогательного вещества, а максимальная зернистость высушенных частиц стероидосодержащих преформций увеличивается менее чем на 30% по сравнению с зернистостью вспомогательного вещества. 5. The technology for the manufacture of homogeneous preforms containing steroids in high concentration for low-dose solid and semi-solid pharmaceutical preparations with a concentrated content of 0.001 to 1% steroid weight is characterized in that a dispersant containing a steroidal active substance is evaporated from a suspension with a dispersed, conventional pharmaceutical excipient substance, moreover, produced by spraying fog, the average droplet diameter of which is greater than the average particle diameter of the auxiliary ETS, and the maximum grain size of the dried particles steroidosoderzhaschih preformtsy increases less than 30% compared with the grain size of the excipient. 6. Технология для изготовления гомогенных преформций, содержащих стероиды высокой концентрации, в соответствии с претензией 5, отличается тем, что обычное фармацевтическое вспомогательное вещество находится в микронизированной форме. 6. The technology for the manufacture of homogeneous preforms containing high concentration steroids, in accordance with claim 5, is characterized in that the conventional pharmaceutical excipient is in micronized form.
RU99113041/14A 1996-12-16 1997-12-15 Steroid-containing homogeneous substance for solid pharmaceutical preparations preparing, method of its making RU2178694C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652196A DE19652196A1 (en) 1996-12-16 1996-12-16 Homogeneous pre-formulations containing steroids for the production of low-dose solid and semi-solid pharmaceutical preparations
DE19652196.3 1996-12-16

Publications (2)

Publication Number Publication Date
RU99113041A true RU99113041A (en) 2001-05-27
RU2178694C2 RU2178694C2 (en) 2002-01-27

Family

ID=7814809

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99113041/14A RU2178694C2 (en) 1996-12-16 1997-12-15 Steroid-containing homogeneous substance for solid pharmaceutical preparations preparing, method of its making

Country Status (13)

Country Link
US (2) US6290931B1 (en)
EP (1) EP0946149B1 (en)
JP (1) JP2001506639A (en)
AT (1) ATE219357T1 (en)
AU (1) AU5748098A (en)
CA (1) CA2275626C (en)
CL (1) CL2004000976A1 (en)
DE (2) DE19652196A1 (en)
DK (1) DK0946149T3 (en)
ES (1) ES2179385T3 (en)
PT (1) PT946149E (en)
RU (1) RU2178694C2 (en)
WO (1) WO1998026762A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906152B4 (en) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Active substance-containing laminates for transdermal systems
EP1171091A1 (en) * 1999-04-16 2002-01-16 Jenapharm GmbH & Co. KG Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102006026578B4 (en) 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Active substance particle-containing transdermal therapeutic system with increased active ingredient flow and process for its preparation and use
DE102008037025C5 (en) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Process for the preparation of crystalline drug microparticles or a solid state drug particle form

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
IE67345B1 (en) 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
IT1252867B (en) * 1991-12-31 1995-06-28 Gentili Ist Spa PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-BIOAVAILABILITY PROGESTERONE
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
DE4426709A1 (en) * 1994-07-20 1996-01-25 Schering Ag Solid dosage forms containing steroidal sex hormones

Similar Documents

Publication Publication Date Title
Rani et al. Self-emulsifying oral lipid drug delivery systems: advances and challenges
CA2264718C (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
Hou et al. Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus®—Solutol® HS15 binary mixed micelles system
Rabbani et al. The influence of formulation components on the aerosolisation properties of spray-dried powders
Zu et al. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique
KR100587962B1 (en) Pharmaceutical compositions containing plasma protein
RU99113041A (en) HEMOGENEOUS PREFERENCES CONTAINING HIGH CONCENTRATION OF STEROIDS FOR THE PRODUCTION OF LOW-DOSED SOLID AND SEMI-HARD PHARMACEUTICAL PRODUCTS
US5935939A (en) Stabilized dispersions of misoprostol
US6447806B1 (en) Pharmaceutical compositions comprised of stabilized peptide particles
Wu et al. A self-microemulsifying drug delivery system (SMEDDS) for a novel medicative compound against depression: a preparation and bioavailability study in rats
GB8924935D0 (en) Small particle drug compositions
MX9707855A (en) Pulmonary delivery of aerosolized medicaments.
KR920017644A (en) Cyclosporine form for pulmonary administration
CA2267498A1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP0951300A1 (en) Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
Coppi et al. Alginate microparticles for enzyme peroral administration
Dong et al. Preparation of ergosterol-loaded nanostructured lipid carriers for enhancing oral bioavailability and antidiabetic nephropathy effects
Patomchaiviwat et al. Formation of inhalable rifampicin–poly (L-lactide) microparticles by supercritical anti-solvent process
Meola et al. Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry
JP3386349B2 (en) Aqueous suspension pharmaceutical composition
Kamalov et al. Self-assembled nanoformulation of methylprednisolone succinate with carboxylated block copolymer for local glucocorticoid therapy
Ruan et al. In vivo and in vitro comparison of three astilbin encapsulated zein nanoparticles with different outer shells
Luo et al. Improving the in vivo bioavailability and in vitro anti-inflammatory activity of tanshinone IIA by alginate solid dispersion
US7704525B2 (en) Lipid microparticles by cryogenic micronization
CA2275626A1 (en) Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations